BestPractice Nordic | Independent clinical perspective in a national context

How does pharma ensure new knowledge reaches and is shared in clinical practice when new indications, diagnostic and treatment options are approved?

This is the challenge pharma faces, but it is also the key to market access success. A process that has not been any easier during the COVID-19 situation.